+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

  • ID: 4833856
  • Report
  • September 2019
  • Region: China
  • 30 Pages
  • China Research & Intelligence
1 of 5
Sales Value of Recombinant Human Thrombopoietin Reached CNY 523 Million in 2017, Representing a CAGR of 27.90% from 2013 to 2017.

In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug-induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30% among patients receiving paclitaxel chemotherapy.

Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia. In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China. By Aug. 2019, it is the only approved Recombinant Human Thrombopoietin product on the Chinese market.

In China, Recombinant Human Thrombopoietin applies to the treatment of patients with thrombopenia (platelet count < 50×109/L) caused by solid tumor chemotherapy when doctors regard it necessary to increase platelet count. It is also used to assist the treatment of patients who have idiopathic thrombocytopenic purpura with a platelet count below 20×109/L when glucocorticoids do not work. It is only applied to patients with thrombopenia and patients facing the increasing risk of bleeding. It is not used to increase platelet count to the normal level.

According to this market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2017, it reached CNY 523 million, representing a CAGR of 27.90% from 2013 to 2017.

It is expected that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase. Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years.

Note: Product cover images may vary from those shown
2 of 5

1 Relevant Concepts of Recombinant Human Thrombopoietin
1.1 Indications for Recombinant Human Thrombopoietin
1.2 Development of Recombinant Human Thrombopoietin in China
1.3 Patents and Government Approval on Recombinant Human Thrombopoietin in China

2 Sales of Recombinant Human Thrombopoietin in China, 2013-2017
2.1 Sales Value of Recombinant Human Thrombopoietin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Thrombopoietin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2013-2017
2.3.1 Injections
2.3.2 Development Trend of Dosage Forms

3 Analysis of Major Manufacturer of Recombinant Human Thrombopoietin in China, 2013-2017
3.1 Market Share of Major Manufacturer of Recombinant Human Thrombopoietin
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China

4 Prices of Recombinant Human Thrombopoietin in China, 2017-2018
4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
4.2 Price Trend of Recombinant Human Thrombopoietin

5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023
5.1 Factors Influencing Development of China's Recombinant Human Thrombopoietin Market
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Patents on Recombinant Human Thrombopoietin in China
Chart Government Approval on Recombinant Human Thrombopoietin in China
Chart Sales of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Market Share of Manufacturer of Recombinant Human Thrombopoietin by Sales Value in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Prices of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Thrombopoietin in China, 2019-2023

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Shenyang Sunshine Pharmaceutical Co., Ltd
Note: Product cover images may vary from those shown
5 of 5

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll